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Abstract
Emerging evidence suggests that microRNAs (miRNAs) play a key role in the regula-
tion of immunological functions including innate and adaptive immune responses, 
development and differentiation of immune cells, and the prevention of autoimmunity. 
The current state of our knowledge in this area is far from being complete, and continued 
investigations will be needed to reveal a better understanding of the miRNA network 
that is involved in the pathogenesis of rheumatoid arthritis (RA). In RA, miRNA plays an 
important role in many different cellular processes. It has been shown that they modulate 
inflammatory responses, proliferation of synoviocytes, and production of metallopro-
teinases in rheumatoid joins and affect the development, differentiation, effector, and 
regulatory functions of T and B cells and cytokine production. The specific circulating 
miRNA species may also be useful for the diagnosis, classification, and prognosis of dis-
eases and prediction of the therapeutic response.
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1. Introduction
Rheumatoid arthritis (RA) is an autoimmune, polygenic disease, which affects millions of 
people worldwide [1]. Human genetic and epigenetic studies have shown that causal factors 
of disease include contributions from at least 40 different genes and the effect of environ-
mental factors. Epigenetics represents a new aspect in autoimmunity, which regulates gene 
expression without alternating DNA sequence. The epigenetic mechanisms are implicated 
in the final interpretation of the encoded genetic information by regulating gene expression, 
and alterations in their profile influence the activity of the immune system. Although there 
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are controversies regarding the involvement of genetic and epigenetic factors in RA etiology, 
it is becoming obvious that the two systems (genetic and epigenetic) interact with each other 
and are ultimately responsible for RA development.
Recently, the list of molecules important for RA pathogenesis has been extended to microR-
NAs (miRNAs), which play a central role in regulating both adaptive and innate immune 
response, development and differentiation of immune cells, and the prevention of autoimmu-
nity [2]. miRNAs regulate protein expression at the posttranscriptional level through reduc-
tion of mRNA stability and inhibition of translation [3]. Human miRNA genes are located on 
all chromosomes except the chromosome Y, are mainly observed in introns (70%), constitute 
only 3% of the human genome, and regulate about 90% of different genes [4, 5]. These mol-
ecules participate in the regulation of the expression of genes involved in the fundamental 
biological processes related to development, proliferation, and apoptosis, as well as patho-
logical processes including autoimmunity [6, 7].
Although we are still at a very early stage in understanding their impact on immunity, 
miRNAs are changing the way we think about the development of the immune system and 
regulation of immune functions. While characterization of miRNA expression patterns in 
RA patients can have potential diagnostic use, new discoveries in cell type-specific miRNA 
expression profile, during the disease progression, may provide further understanding of RA 
pathogenesis. Because miRNAs are stable in plasma or serum, they may be use as biomark-
ers for the prediction of the disease activity, the differentiation of RA from other rheumatic 
diseases, or the monitoring of current therapy.
2. Biogenesis
Mature miRNAs are single-stranded, small, noncoding RNAs about 22 nt long. The biogenesis 
of miRNAs is under tight temporal and spatial control. It starts in nucleus where long primary 
miRNAs (pri-miRNAs) are transcribed by RNA polymerase II. miRNA sequences are located 
within various genomic contexts including both intronic and exonic regions. Pri-miRNA 
transcription is regulated by transcription factors like p53, MYC, ZEB1, ZEB2, and myoblast 
determination protein 1 (MYOD1). Additionally, epigenetic factors (DNA methylation and 
histone modifications) regulate this process. The resulting transcript is capped with a specially 
modified nucleotide at the 5ʹ end (MGpppG) and polyadenylated with a poly(A) tail at 3ʹ end. 
Pri-miRNA is subsequently cleaved by the so-called microprocessor complex and forms a 
precursor hairpin miRNA (pre-miRNA). Microprocessor complex is composed of RNase III 
enzyme—Drosha and of the RNA-binding protein DGCR8 (also known as Pasha). In the next 
step, pre-miRNA is exported from the nucleus to the cytoplasm in a process involving expor-
tin-5 (Exp-5) and GTP-binding nuclear protein RAN•GTP. Following translocation to the 
cytoplasm, the pre-miRNA is cleaved, by the cytoplasmic RNase III enzyme Dicer, into 19- to 
23-nucleotide mature miRNA duplexes. Although either strand of the duplex may potentially 
act as a functional miRNA, only one is usually loaded into the RNA-induced silencing com-
plex (RISC) where the miRNA and its mRNA target interact (reviewed by Ref. [8]). miRNA 
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guides RISC complex to the 3ʹ-untranslated region (3ʹ-UTR) of target mRNA to prevent trans-
lation of the mRNA into protein. The other (termed the passenger) strand is degraded or 
released from the cell. There are few different mechanisms of miRNA export from the cell. 
miRNAs may be released from the cell by exosomes or microvesicles. Moreover, miRNAs can 
form complexes with high-density lipoproteins or RNA-binding proteins such as Ago2 and 
in that form circulate outside the cell. Exact mechanism of how these complexes are trans-
ported from the cell still remains unknown. They may be released passively, after cell death, 
or actively through specific membrane channels or proteins. Interestingly, other pathways for 
miRNA biogenesis are also emerging. Examples include those that are independent of Drosha 
or Dicer, “mirtrons”—some small nucleolar RNAs (snoRNAs) and endogenous short hairpin 
RNAs (shRNAs) [8–10].
3. Mechanism of action
Small noncoding miRNA has the potential to broadly influence various molecular path-
ways via suppression of unwanted mRNA transcripts. These highly conserved ~22-nucleo-
tide long miRNAs recognize its mRNA target through “seed region” that is located at the 5ʹ 
end of miRNA and span from nucleotide positions 2–7. It binds to mRNAs’ complementary 
sequence usually located within 3ʹ-untranslated region (3ʹ-UTR). miRNAs silence its target 
expression via various mechanisms leading to mRNA degradation or preventing mRNA from 
being translated [11]. After specific mRNA sequence recognition, argonaute (AGO) protein 
recruits factors that induce translational repression or mRNA degradation. Target mRNA 
destination depends probably on the sequence complementarity level with miRNA—com-
plete complementarity leads to mRNA degradation and partial complementarity to transla-
tional inhibition, although there are exceptions to this rule. Interestingly, some target mRNAs 
can be exclusively repressed by degradation or translational inhibition, but often it occurs by 
combination of these two processes (reviewed in Refs. [9, 12]).
3.1. Inhibition of translation
There are still many unknowns around mechanism of translational repression of target 
mRNA. It is not clear whether miRNA represses translation at the step of translational initia-
tion or posttranslational level [13]. Significant number of studies support model of repres-
sion at posttranslational level (protein degradation) or at late stage of translation (premature 
termination or impaired elongation). These studies demonstrated that miRNA-repressed 
mRNAs maintained the same distribution pattern across polyribosomes compared with non-
repressed mRNAs [14, 15]. However, other studies showed contradictory results, indicating 
that repression occurs at the translational initiation step. There are many models proposing 
mechanism of this process.
Almost all proposed models consider GW182 interaction with one of the Ago proteins as a 
first step of translational repression. In first model, GW182 disrupts the association between 
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eIF4G and poly-A-binding protein (PABP) and prevents the circularization required for effi-
cient translation. In the second model, formation of the mRNA 40S preinitiation complex 
occurs, but miRISC complex prevents 60S ribosome from joining it, resulting in translation 
repression. The third scenario assumes that ribosome is detached earlier leading to premature 
translation termination. Another possible proposed mechanism assumes that target mRNA 
is accumulated in so-called processing bodies (P-bodies) that prevents from interaction with 
translational machinery [12, 16].
3.2. Destabilization of target mRNA
There are two mechanisms of miRNA-mediated mRNA degradation-specific cleavage and 
non-cleavage mRNA degradation. mRNA degradation by miRNA requires Ago, GW182, and 
the cellular decapping and deadenylation machinery. miRNA sufficient complementarity 
to target mRNA leads to its specific cleavage. The process is facilitated through Ago pro-
tein slicer activity. Ago cleavage site is determined by miRNA sequence, not mRNA paring 
residues, and occurs within mRNA pairing site to the 10th and 11th residues of miRNA. 
Therefore, the degree of complementarity at the 3ʹ end of miRNA is more important than at 
the 5ʹ end. After cleavage miRNA remains intact and is able to mediate another mRNA silenc-
ing [17, 18]. Non-cleavage degradation of target mRNA involves GW182. GW182 forms a 
bridge between RISC and CCR4-NOT deadenylase complex leading to mRNA deadenylation 
and decapping [19, 20].
4. Biological function of microRNAs
MicroRNAs as endogenous regulatory molecules are present in plant, animal, and human 
cells, and they are essential for proper development and functioning of the organism. Their 
main role is associated with posttranscriptional regulation of the expression of numerous 
genes in both pathogenic and pathological aspects of diseases (Figure 1) [21, 22]. miRNAs 
together with Argonaute (AGO) proteins, forming a core of the miRNA-induced silencing 
complex (miRISC) which mediates gene silencing [23]. Each miRNA has several different tar-
gets, and many of mRNAs are subject to regulation by more than one miRNA [24]. Over 60% 
of human genes are controlled by miRNAs, which indicates the great importance of these 
molecules [23].
The continuous miRNA-mRNA interaction is essential for miRNA function. miRNA genes 
are present either as independent transcription units or located in introns and exons of other 
genes. Gene silencing can be done either through degradation of a specific mRNA or as a 
result of the inhibiting of the transcript translation. Furthermore, the mechanisms by which 
miRNA complementarity to its target mediates repression are varied [25, 26]. In some cases 
the miRNA binds with complementarity in the seed region (nucleotides 2–8 of the miRNA) 
within the 3ʹ-untranslated region (UTR) of mRNA and leads to inhibit target gene translation 
or less commonly within the 5ʹ-UTR region that enhancement of translation [25, 27]. But on 
the other hand, the miRNA-mRNA interaction occurs in the central region (bases ~9 to 12) 
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leading to the mRNA cleavage and subsequent degradation [26]. Generally, miRNAs do not 
act to completely silence their targets, but rather decrease expression. However, the identifica-
tion of the type of interaction between miRNA and mRNA remains a very important focus to 
understand control in gene expression [26, 27].
Figure 1. Biological functions of microRNAs.
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In the last years, a large number of studies examined cellular miRNA profiles, where expres-
sion changes under stress conditions, in cancer, and in other diseases. Distortion of miRNA 
expression may result in abnormalities in the course of numerous cellular processes, such 
as development, differentiation, proliferation, inflammation, cell fate determination, apopto-
sis, signal transduction, organ development, hematopoietic lineage differentiation, host-viral 
interactions, osteogenesis, and stem cell and germ line proliferation [22, 24, 25, 27–30]. These 
discoveries may help to clarify molecular mechanisms of diseases and based on this knowl-
edge and may help to develop new drugs. However, since the amount of miRNA may be 
differ, its total quantity in the different type of cells and gene silencing efficiency depends on 
the concentration of mRNA targets interpretation of miRNA expression, as well as profiles, 
including clinical studies, should be performed with attention.
While the majority of miRNAs are found intracellularly, miRNAs may also function beyond 
RISC, as an extracellular, in virtually all known body fluids [31, 32]. The extracellular miR-
NAs are secreted into exosomes or microvesicles [26]. However, little is known about the 
origin of body fluid miRNAs in both healthy and disease conditions or what factors affect 
their levels in serum/plasma [31]. One hypothesis suggests that blood cells are the major con-
tributors to extracellular miRNAs in the serum or plasma, but another hypothesis speculates 
that organs may also contribute to extracellular miRNAs because tissue-enriched miRNAs 
(e.g., miR-122 in the liver, miR-133 in the muscle, miR-208 in the heart, and miR-124 in the 
brain) are also detected in serum or plasma [31]. Independently of existing hypotheses, expla-
nation of the origin of the extracellular miRNA would increase our understanding of their 
potential pathophysiological significance. In addition, regardless of their origin, extracellu-
lar miRNAs are extremely stable, and their concentration did not significantly change with 
prolonged incubation of blood plasma at room temperature [23]. The level and composition 
of extracellular miRNAs in body fluids, such as serum or plasma, are correlated with several 
pathological conditions, including cancer, diabetes, inflammatory diseases, as well as tissue 
injury [31]. Moreover, expression patterns of miRNAs are also different between disease state 
and normal tissue [26] and appear to be tissue specific [21]. However, current knowledge 
about the biological function of extracellular miRNAs is in its infancy stage. Nevertheless, 
it seems that extracellular miRNAs may act as signaling molecules and mediate distant cell-
cell communication. Cross talk mediated by these miRNAs may provide new insights into 
the understanding of the mechanisms underlying various dysfunctional conditions. Cross 
talk through these miRNAs may provide new look at the understanding of the mechanisms 
underlying the various dysfunctional states [31].
5. Rheumatoid arthritis as a chronic civilization disease
Rheumatoid arthritis is one of the most prevalent chronic inflammatory diseases and is char-
acterized by progressive joint inflammation, by destruction of articular cartilage and underly-
ing bone, and by synovial hyperplasia. RA can affect any joint, with a joint cavity lined by 
synovial membrane (SM) [33, 34]. The disease process is highly variable, with periods of exac-
erbation and remission, and uncontrolled inflammation leads to progressive joint damage, 
pain, long-term disability, and reduced quality of life in many patients [34, 35].
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Although RA affects people all over the world, women are affected three times more than 
men with the peak of incidence between 35 and 55 years of age [33, 36–38]. The incidence of 
rheumatoid arthritis is relatively constant in most European and North-American popula-
tions and is estimate between 0.5% and 1%. RA incidence decreases from north to south and 
from urban to rural areas. A positive family history increased the risk of RA, and we can see 
that the familial RA occurrences are about 10–30% of patients, whereas the concordance rate 
is 12–15% in monozygotic twins and 3–4% in dizygotic twins [39].
RA is pathologically heterogeneous and it is classified among systemic autoimmune dis-
orders because of the presence of rheumatoid factor (RF) and other autoantibodies such as 
anticitrullinated protein autoantibodies (ACPAs) [35, 40, 41]. RF is present in about 60–85% 
patients with RA; ACPAs appear to be equally sensitive (75%) and highly specific: 94% for the 
established disease and 61% for early RA, which may be able to serve as an early diagnostic 
marker and prognostic factor of joint destruction [42].
Although the exact etiology remains an active area of worldwide research, it is generally 
accepted that the RA is a multifactorial disease of which pathogenesis is defined by genetic 
and environmental factors [21]. Genetic predisposition is responsible for 50–60% of the risk 
of developing RA [43, 44]. A genetic link to RA was established through the observation 
of familial clustering of RA and large-scale genome-wide association studies (GWAS) [45]. 
Moreover, it is suggested that only the specific combination of genetic factors in an individual 
might determine the outcome of the disease [7]. HLA-DRB1 alleles, which share a common 
sequence, known as the “shared epitope” account for approximately 30% to 50% of overall 
genetic susceptibility to RA. Probably some other genes associated with components of the 
innate and adaptive immune system and other mechanisms such as epigenetics may also play 
a role in the pathogenesis of RA. Epigenetic mechanisms are engaged in the final interpreta-
tion of the genetic information by regulation of the gene expression, and changes in their pro-
file influence the activity of the immune system [46]. The change in epigenetic mechanisms is 
implicated in the final interpretation of the encoded genetic information by regulating gene 
expression; on the other hand, genetic mutations in epigenetic regulators may alter the epi-
genetic profile. Consequently, epigenetics and genetics can be two sides of the same coin, as 
has been determined in the field of rheumatoid arthritis research [46]. Future challenges are 
understanding and leveraging of the role of genetics and epigenetic modifications, as well as 
their functional characteristics in RA pathogenesis and translation of fundamental discoveries 
into clinical practice [47].
6. miRNAs in the pathogenesis of rheumatoid arthritis
Up to date about 2,500 different miRNAs were discovered in humans. From all of these miR-
NAs, some may play an important role in the regulation of the innate and adaptive immune 
responses in patients with RA. Increasing number of studies has shown that abnormal miRNA 
expression in different fluids or cells from RA patients may lead to inflammation, cytokine 
signaling, bone degradation, and invasive behavior of resident cells [6]. In addition, there is 
growing evidence that miRNAs as crucial mediators of inflammation may also regulate the 
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plasticity and the effector functions of differentiated Th-cell subsets [24, 48]. miRNAs on the 
one hand have an important role in defining and maintaining the gene expression program-
mer of differentiated Th17 cells, but on the other hand, the miRNA expression in regula-
tory T cells (Treg cells) is important for the maintenance of self-tolerance. And as we know, 
abnormally activated inflammatory Th cells and defective Treg cells play primary role in the 
pathogenesis of RA. Moreover, miRNA expression may be also diverse in the different stages 
of RA progression, allowing miRNAs to help monitor disease activity and help to understand 
its pathogenesis [6]. Understanding the potential link between miRNAs and the pathogenesis 
of RA may lead to future insights into disease diagnosis and treatment [4, 22].
The first evidence that miRNAs may be involved in the molecular mechanisms of RA arose in 
2007 with the recognition, in the serum of RA patients, of autoantibodies directed against GW 
bodies that are cytoplasmic structures for storage and/or degradation of mRNA [4]. The first 
miRNAs that shown abnormal expression within the inflamed joints of RA patients includes 
miR-16, miR-146a, and miR-155 [4, 49]. These multifunctional miRNAs play a central role in 
the inflammatory response and immune dysfunction, in response to microbial components, 
and are upregulated after immune cell maturation [4]. miR-16 and miR-146a play a role in 
the regulation of the tumor necrosis factor alpha (TNF-α) signaling, which is one of the key 
cytokines involved on the pathogenesis of RA [2, 50]. Furthermore, miR-155 could suppress 
matrix metalloproteinases (MMPs) through the interaction with proinflammatory cytokines 
and Toll-like receptor (TLR) ligands and lead to modulation of joint inflammation [2, 51]. 
miR-146a and miR-155 are responsible for the maintenance of immune homeostasis, and 
their expression changes in RA may alert cytokine secretion from different immune cells [30]. 
Moreover, “miR-146a and miR-155 are considered the ‘yin and yang’ of inflammation as these 
miRNAs are negative and positive regulators of inflammatory responses, respectively” [30]. 
miR-155 promotes T-cell–mediated tissue inflammation by the regulation of the Th1- and 
Th17-cell response, and it also through the targeting of SOCS1, a negative regulator of IL-2 
signaling, controls Treg cell homeostasis [24]. Like miR-155, miR-146a is highly expressed in 
Treg cells. Furthermore, in contrast to miR-155, miR-146a required for the suppressive activ-
ity of Treg cells is essential for the ability of Treg cells to restrain IFN-γ-mediated pathogenic 
Th1 responses and associated inflammation [24, 50]. Whereas miR-146a rather reduces the 
proinflammatory immune responses, miR-155 enhances inflammatory processes [48]. The 
main advantage of the detection of miR-16 and miR-146a in serum/plasma is that this opens 
the possibility to test as a biomarker to monitoring disease activity/course, because both 
have shown positive correlation with C-reactive protein (CRP) and disease activity score in 
28 joints (DAS28) [4, 48].
Other tissue and/or extracellular miRNAs have been also shown to be associated with RA 
(Table 1), and those miRNAs can regulate specific cytokine pathways, thus leading to inflam-
mation [27]. Characteristics of miRNA profile in patients with RA suggest putative functions 
of these factors in cytokine secretion and signaling during chronic inflammatory processes in 
the joints. The miR-10a, miR-16, miR-23b, and miR-203 may serve to fine-tune cytokine sig-
naling, and they may be responsible for the induction of autoimmune inflammation [24, 50]. 
Upregulation of miR-16 and miR-203 in synovium of RA patients is responsible for the regula-
tion of the TNF-α signaling and for increased matrix metalloproteinases (MMPs), as well as 
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IL-6 production, respectively, thus indicating that these miRNAs may plays a role as proin-
flammatory and joint destructive factors [27, 50]. In contrast, miR-10a and miR-23b, which are 
downregulated in RA synovial tissue, regulate signaling pathway of proinflammatory cyto-
kines such as IL-1β, TNF-α and IL-6, IL-8, and IL-17, as well as MCP-1 and MMPs, and they 
may be a strong pathological factors that play a critical role in the onset and progression of 
RA [50, 52]. The cytokines are also a key regulator of Th17/Treg imbalance, which participate 
in the immune dysfunction. The immune dysfunction in RA patients is found to be induced 
by decreased expression of miR-21, which may suppress Treg development while promoting 
Th17 differentiation. Moreover, this miRNA may serve as a novel regulator of Th17/Treg bal-
ance in autoimmune diseases including RA [53]. Another miRNA, which participate in the 
balance between Th17 and Treg cells, is miR-10a, which exhibits high expression in natural 
Treg cells, limiting the conversion of inducible Treg cells into follicular helper T cells (Tfh 
cells) and inhibiting Th17 differentiation [54].
miRNAs Localization Target gene Changes Function
miR-10a PBMCs, DCs, nTreg 
cells
STAT - Signal transducer 
and activator of 
transcription
Foxp3, Bcl-6, Ncor2
Downregulation - Control IL-6 and 
IL-21 signaling
- Regulate the stability 
of Treg cells
- Limit the conversion 
of iTreg cells into Tfh 
cells
- Inhibit Th17 
differentiation
miR-16 PBMCs, plasma, 
synovial fluid
TNF-α Upregulation - Marker of disease 
activity
miR-17-92 RASFs, FLS, B cells MMP-1, IL-6, IL-8, MCP-
1, RANTES
Downregulation - Modulate apoptosis, 
proliferation
- Joint inflammation 
and destruction
- Regulated 
proinflammatory 
cytokine production
miR-21 plasma, PBMCs, 
CD4+T
Foxp3
STAT3
Upregulation - Regulate th17/Treg 
balance
miR-22 RASFs CYR61 Downregulation - Synovial tissue 
hyperplasia
- Th17 differentiation
miR-23b ST IL-1β
TNF-α
IL-17
Downregulation - Induction of 
autoimmune 
inflammation
miR-24 plasma TGF - transforming 
growth factor-β1
Upregulation - Marker of disease 
activity
- Enhance the 
inflammation
miR-26a PBMCs, plasma Upregulation - Diagnostic 
biomarker
miR-30a ST BECN1 - beclin 1 Downregulation - Reduce apoptosis
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Several of different cells, such as T cells, B cells, or macrophages, have been identified as the 
sources leading to local joint deformation [55]. These cells are the sources of some miRNAs that, 
through the regulation of the osteoclastogenesis and differentiation of articular chondrocytes, 
are implicated in the renewal of cartilage and bone degradation [50]. The best known miRNAs 
involved in joint destruction are miR-146a and miR-155. However, recently marked expression 
of other miRNAs, miR-223 and miR-19a/b, have been shown within inflamed joint in patients 
with RA [3, 4, 51, 56]. miR-223 overexpression suppressed the production of osteoclasts and 
expression of osteoclast-marked genes [50]. Moreover, an inverse correlation between the 
miRNAs Localization Target gene Changes Function
miR-34a RASFs XIAP Downregulation - Contribute to 
apoptosis
miR-124a RASFs, synoviocytes CDK-2
MCP-1
VEGF
Downregulation - Regulator of RASFs 
and autoimmune 
inflammation
- Contribute to 
angiogenesis
miR-125b serum, blood NF-κB Downregulation - Induce of excessive 
inflammation
miR-146 SF, ST, RASFs, 
PBMCs, blood, 
serum, T cells, B 
cells, monocytes, 
macrophages
TLR4, NOX4 - NADPH 
oxidase 4,
Upregulation - Marker of disease 
activity
- Inhibit Th1-mediated 
responses
- Suppress activity of 
Treg cells
- Modulated apoptosis
miR-155 ST, SF, RASFs, 
PBMCs, blood, 
serum, macrophages
SHIP-1, SOCS-1MyD88, 
MAP3K10 - Mitogen-
Activated Protein Kinase 
Kinase Kinase 10
Upregulation - Regulate cytokine 
expression
- Require for 
homeostasis and 
function of Treg cells
miR-203 RASFs MMP-1, NF-κB Upregulation - Participate in joint 
inflammatory state
miR-223 PBMCs, RASFs, 
ST, plasma, 
macrophages, 
monocytes, T cells
Upregulation - Regulate 
osteoclastogenesis
miR-451 T cells, neutrophils p38 MAPK - mitogen-
activated protein 
kinases, CPNE3 - copine 
3
Downregulation - Role in inflammation
PBMCs, peripheral blood mononuclear cells; RASFs, RA synovial fibroblasts; FLS, fibroblast-like synoviocytes; 
MMP-1, matrix metalloproteinase-1; MCP-1, monocyte chemoattractant protein-1; RANTES, regulated on activation, 
normal T cell expressed and secreted; ST, synovial tissue; XIAP, X-linked inhibitor of apoptosis protein; CDK-2, cyclin-
dependent kinase 2; VEGF, vascular endothelial growth factor; SF, synovial fluid; SHIP-1, Src homology 2-containing 
inositol phosphatase-1
Table 1. Candidate miRNAs for the RA pathogenesis.
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plasma miR-223 levels and the tender join count was observed [4]. The expression of the miR-
19 was downregulated in RA fibroblast-like synoviocytes (FLS), and this plays a role in joint 
destruction, in response to TLR stimulation [57]. miR-19a and miR-19b negatively regulate the 
synthesis of IL-6 and regulate the expression of MMP3, suggesting a role of both these miRNAs 
in protecting patients with RA from joint inflammation and consequently destruction [57].
The above-addressed miRNAs are not only important positive/negative regulators of inflam-
matory response and immune dysfunction, but they also may be useful for the prediction of 
the disease course and identification of early pathological events, as well as beneficial for the 
development of new therapeutic strategies [50].
7. Therapeutic potential of miRNA in treatment of rheumatoid arthritis
The discovery of the miRNA as regulators of gene expression was followed by a wave of 
interest and intensive studies for elucidating their role both in physiological and pathologi-
cal conditions. The obtained results raised hopes for the possibility of developing a num-
ber of therapeutic uses of these molecules. miRNAs are characterized by many features that 
make them excellent candidates for biomarker drug entity. These molecules are small with 
sequence well-known and often conserved among species, which are very attractive features 
from a drug development standpoint.
Some alterations of miRNA expression have been associated with many human disorders 
including autoimmune diseases, metabolic disorders, and genetic diseases. By targeting 
cells affected with improper miRNA expression, the normal balance of the expression can be 
restored. Novel systems to achieve targeted modulation of specific miRNA in vivo were devel-
oped. By controlling the miRNA that regulate mRNAs in cells, they can be used for therapeutic 
treatment for certain cellular disorders. Individual miRNAs can be targeted using specifi-
cally modified antisense oligonucleotides—anti-miRNAs. By virtue of specific modifications, 
anti-miRNAs gain improved binding affinity, nuclease resistance, and in vivo delivery. For 
example, 2′-O-methoxyethyl phosphorothioate (MOE) or N,N-diethyl-4-(4-nitronaphthalen-
1-ylazo)-phenylamine (ZEN) oligonucleotide modifications were generated to improve bind-
ing affinity and block exonuclease degradation. Other examples are anti-miRNAs conjugated 
to cholesterol to improve its uptake into the cell through the membrane. Furthermore, the 
great potential seems to lie in the ability of individual miRNAs to regulate the expression of 
many related genes, which could lead to the regulation of whole signaling pathways or meta-
bolic modulation using one or more miRNA molecules. On the other hand, effect on multiple 
targets also involves high risk due to the unexpected side effects. Nevertheless, important 
role of microRNA in regulation of all cellular processes and constant tissue-specific expres-
sion indicates its high potential for diagnostic and therapeutic usage [9]. Moreover, miRNA 
properties and characteristics indicate their excellent potential to be clinical biomarkers. It 
is well-known that perfect biomarker should be stable in a sample, easy to assess, specific, 
and sensitive to relevant changes, and miRNA fulfil these criteria. Although cell endogenous 
miRNA is not very stable and easily degraded, it was discovered that miRNA detected in 
the blood [21] (plasma, platelets, nucleated blood cells) and synovial fluid [32] is stable and 
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in the case of miRNA in the blood even resistant to harsh condition like high temperature, 
high and low pH, or multiple freeze-thaw cycles. miRNAs require this surprising stability 
due to microparticles (exosomes, microvesicles, and apoptotic bodies), RNA-binding proteins 
(like Ago2), or lipoprotein complexes [high-density lipoprotein (HDL)] that protect them 
from degradation. The value of miRNA as molecular biomarkers for diagnosis, prognosis, 
and prediction of therapeutic response is widely documented in cancer. Another advantage 
that raises interest in the use of circulating miRNAs as clinical biomarkers is fact that there 
are highly sensitive and specific miRNA detection methods in a quantitative manner, such as 
real-time PCR, sequencing, and microarrays. In that respect, circulating miRNAs offer many 
features to make them an attractive class of biomarkers [10].
7.1. miRNA as potential therapeutic agent for RA treatment
The involvement in the pathophysiology of RA coupled with specific characteristics of miR-
NAs has triggered the scientific community to start exploring the possibilities of viewing 
miRNAs as therapeutic entities. Especially the potential of a single miRNA to modulate sev-
eral genes and affect multiple distinct disease-regulatory pathways simultaneously makes 
miRNAs particularly attractive candidate targets for chronic inflammatory disease as RA. 
However, only a limited number of groups have explored the therapeutic potential of miR-
NAs in RA.
Among many approaches considering belief that one miRNA is able to control several genes 
and pathways, targeting miR-155 represents the most encouraging miRNA-based therapeutic 
strategy today.
Currently available data clearly show that miR-155 is crucial for the development of arthri-
tis by increasing production of proinflammatory cytokines and promoting differentiation of 
antigen-specific T cells and antigen-specific antibodies. Interestingly Kurowska-Stolarska et 
al. observed that miR-155 deficiency is protective against development of collagen-induced 
arthritis (CIA) in mice. Inhibition of miR155 was associated with impaired production of 
proinflammatory cytokines, development of the autoreactive Th17 cells, production of anti-
collagen II antibodies, and lack of articular inflammation. MiR-155-deficient mice display 
reductions in both joint inflammation and bone erosion [58]. Beside miR-155, several miRNAs 
have been implicated in diseases that affect cartilage or have been identified as essential in 
cartilage homeostasis or repair. For example, the expression of miR-26a was shown to be 
reduced in splenic cells isolated from rats with induced arthritis. Treatment with methotrex-
ate restored the expression miR-26a to levels comparable to those of non-arthritic controls, 
and repeated miR-26a injections stabilized disease severity and reduced synovitis, but had 
no effect on joint destruction [59]. miR-26a can affect bone formation, through angiogenesis 
and osteogenesis-positive regulation. Overexpression of miR-26a resulted in enhanced bone 
regeneration coordinated with improved vascularization in mouse, leading to complete repair 
of the defect [60]. Nakasa et al. demonstrated in vivo and in vitro that miR146a is also able to 
prevent bone/cartilage destruction. They observed that in CD14+ human cells transfected by 
dsmiR-146a and treated with M-CSF and TNFα or Receptor Activator for Nuclear Factor κ 
B Ligand (RANKL) for osteoclastogenesis induction—tumor necrosis factor receptor-associ-
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ated factor 6 (TRAF6) protein levels—and the number of Tartrate-resistant acid phosphatase 
(TRAP)-positive cells were significantly reduced compared to cells transfected with nonspe-
cific dsRNA. Also osteoclast function was significantly inhibited in those cells. Furthermore 
they tested the efficacy of ds miR-146a inhibition of bone destruction in vivo and observed 
that the extent of bone and cartilage destruction was reduced in arthritic mice injected with ds 
miR-146a compared to mice treated with nonspecific dsRNA. However, despite the inhibition 
of bone/cartilage destruction by ds miR-146a injection, there was no significant difference in 
the arthritis score between the ds miR-146a-treated group and the nonspecific dsRNA-treated 
group suggesting that administration of ds miR-146a alone may not be a sufficient treatment 
for RA [61]. Another group that observed underexpression of miR-451 in neutrophils isolated 
from patients with RA used a systemic administration to restore normal expression level of 
miR-451 in mice with monogenic model of autoimmune arthritis (SKG mice). This approach 
led to reduction in the number of neutrophils in synovium, by suppressing their migration. 
This “miR-451” treatment resulted in reduced severity of arthritis in SKG mice suggesting its 
potential as therapeutic agent in RA [62]. miR-124 was also found to negatively regulate osteo-
clastogenesis of mouse bone marrow macrophages. In rats with adjuvant-induced arthritis 
(AIA), miR-124 expression level was significantly decreased. Nakamachi et al. observed that 
injection of miR-124 into rat AIA joints reduces disease severity. It is probably due to miR-
124-mediated targeting of NFATC1, a master transcription factor of osteoclast differentiation. 
This suggests a potential of miR-124 as future therapeutic entity used for arthritis ameliora-
tion [63, 64].
Studies on miRNA-based treatment strategies are rare, but we can expect that these therapies 
will be developed in the near future. Although mentioned above preclinical studies demon-
strate the potential of delivering therapeutic miRNAs, numerous challenges still remain in 
designing effective and safe delivery of these agents in a cell- or tissue-specific manner. We 
are still lacking evidence of similar miRNA deregulation in human RA and of the ex vivo 
correction of disease phenotypes in patient-derived cell or tissue samples. Furthermore, the 
cellular mechanisms that could explain observed clinical benefits of miRNA therapies still 
need to be characterized in depth.
7.2. miRNA as RA diagnostic biomarkers
The knowledge about potential value of miRNA as molecular biomarkers for diagnosis, prog-
nosis, and prediction of therapeutic response in RA has been expanded. Several abnormally 
expressed miRNAs in circulation or inflamed joints in RA have been identified. That suggests 
theirs potential to be used as biomarkers that help to establish or confirm a diagnosis, moni-
tor the degree of immunologic activity or inflammation, or provide prognostic information 
regarding disease progression and severity. There are few studies that referred the possibility 
to use plasma and synovial miRNAs as diagnostic biomarkers that distinguish healthy people 
from patients with RA or another disease with similar symptoms. For example, upregulation 
of miR-146a, miR-155, and miR-223 has been shown in various compartments such as serum, 
blood, synovial fluid, and tissues in patients with RA. Many studies observed elevated levels 
of expression of miR-146a in different tissues from RA patients; some of them confirm that 
miR146a level is correlated with disease activity that highlights its significance in RA patho-
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genesis and diagnostic biomarker potential [51, 65–67]. Elsayed et al. confirmed significant 
upregulation of miR-146a expression in the whole blood of patients with RA and that miR-
146a in diagnostic performance was better than anti-CCP and RF. miR-146a expression level 
allowed for distinguishing RA patients from healthy controls (HCs) with high sensitivity and 
specificity (96 and 100%, respectively). Moreover, its expression level was positively correlated 
with disease activity [68]. It is important to note that these studies are limited by a relatively 
small number of patients and were conducted in patients from different races and ethnicities. 
Similarly Kriegsmann et al. observed that miR-146a, miR-155, and miR-223 were significantly 
elevated in RA compared to osteoarthritis (OA) synovial tissues. The sensitivity and specific-
ity for the detection of RA were 0.76/0.80 for miR-146a, 0.80/0.95 for miR-155, and 0.86/0.81 for 
miR-223. In combination these miRNAs gave even better results as RA diagnostic biomarker 
with a sensitivity and specificity of 0.84/0.91, respectively [69]. Murata et al. performed com-
prehensive array study to find out which miRNAs in plasma samples significantly differentiate 
patients with RA (patients with high disease activity, who had never received any biological 
therapy such as the anti-TNF agents) from HCs. They tested eleven preselected candidate miR-
NAs in 102 patients with RA and 104 HCs and found out that miR-125a-5p, miR-26a, and miR-
24 expression levels gave the best results. For miR-24, miR-26a, and miR-125a-5p, the values 
of sensitivity and the specificity were 63.7 and 89.5%, 53.9 and 94.3%, 64.7 and 89.5%, respec-
tively. These results suggest that plasma miR-24, miR-26a, and miR-125a-5p can be diagnostic 
biomarkers with high specificity. The combinations of miR-24, miR-30a-5p, and miR-125a-5p 
(termed ePRAM for “estimated probability of RA by plasma miRNAs”) with sensitivity 78.4% 
and specificity 92.3% are more efficient for RA differentiation and have higher diagnostic sig-
nificance as biomarkers in RA. These selected miRNAs correlate with disease activity (besides 
miR-125a-5p) erythrocyte sedymentiation rate (ESR), CRP, RF, ACPA, or DAS28 and not only 
can be markers for diagnosis of RA but also for disease activity of RA [70]. In a small study, 
Murata et al. assessed the diagnostic usefulness of plasma miR-132 for patients with RA or OA. 
They showed that plasma miR-132 differentiate RA and OA patients from healthy controls 
(83.8% of sensitivity and 80.7% of specificity for RA and 84.0% of sensitivity and 81.2% of speci-
ficity for OA) but failed to distinguish them from each other. Interestingly they observed that 
miRNAs in synovial fluid (miR-16, miR-146a, miR-155, and miR-223) from RA patients were 
significantly higher than those of patients with OA, suggesting that synovial fluid miRNAs 
could be a useful tool for diagnosis of RA from OA; however, they did not correlate with clini-
cal variables of RA including DAS28 [32].
Although, evidence that supports the therapeutic potential of miRNA-based strategies is grow-
ing, further investigations are required to find suitable miRNAs for utilizing as biomarkers for 
diagnosis, predicting drug efficacy in order to plan optimal management of RA patients.
7.3. miRNA as response to treatment biomarkers
Almost all newly diagnosed RA patients enter their treatment with methotrexate monother-
apy. If it fails (and it is ineffective in 66% of patients), other disease-modifying antirheumatic 
drugs (DMARD) and then one of biologic agents are prescribed. Considering that each type 
of biology treatment targets different inflammatory mechanisms, sometimes it may take 
some time to find the best therapy for a patient. Although biological medicines significantly 
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improved RA treatment, there are still some stumbling blocks to be overcome. The major 
problems of the treatment with biologics are serious potential side effects and high cost of 
biologics. Currently clinical and serological markers that sufficient predict disease outcome 
are unavailable. Therefore one of the most challenging issues is the identification of biomark-
ers that will predict therapeutic outcome and thus would improve patient care and medical 
cost-effectiveness. Potential value of miRNAs as molecular biomarker for prognosis treat-
ment response is still unexplored in RA. However, there are several reports demonstrating 
possibility to use them as therapy outcome predictors [6, 71]. Duroux-Richard and Jorgensen 
proposed hsa-miR-23a-3p and hsa-miR-223-3p as predictors of therapy response and bio-
markers of response to anti-TNFα/DMARDs combination therapy. Strong increase in hsa-
miR-23a-3p and hsa-miR-223-3p expressions indicated good response to treatment. Moreover 
those changes significantly correlated with clinical and inflammatory parameters (such as 
DAS28, CRP, or ESR). Most importantly expression level of these miRNAs showed its poten-
tial to predict therapy outcome. hsa-miR-23-3p and hsa-miR-223-3p levels were predictors of 
nonresponse to anti–TNF-α/DMARD combination treatment with a sensitivity of 62.5 and 
57.1% and a specificity of 86.4 and 90.2%, respectively. The combination of these two miRNAs 
demonstrated an increase in both the sensitivity (62.5%) and specificity (91.5%) in relation to 
those given by each miRNA alone [6].
Another circulating miRNAs suggested to be a potential predictive biomarker of response to 
RA treatment was miR-125b. Duroux-Richard et al. observed that miR-125b expression sig-
nificantly distinguish RA patients from healthy donors and OA patients but not from patients 
with other rheumatic disorders like tumor necrosis factor receptor-associated periodic 
syndrome (TRAPS) or spondyloarthritis (SpA). Results obtained in this study also showed 
that high expression of miR-125b was associated with good response to rituximab therapy. 
Serum expression levels of tested miRNA before treatment were significantly higher in good 
responders than in nonresponders. However, it was not correlated with disease activity 
parameters. These data suggest miR-125b might be considered as a biomarker that predicts 
therapy response but is not useful as disease activity marker [72].
The realization of personalized medicine requires comprehensive understanding of genetic 
and nongenetic factors that may be responsible for drug response. Although several miRNAs 
appear to be attractive molecular biomarkers, discovery of perfect biomarkers for RA diag-
nosis and prediction of treatment outcome is still in the future. Better understanding of the 
role of miRNAs in RA pathogenesis and identification of specific miRNA expression patterns 
in RA may provide novel molecular prognostic and diagnostic biomarker markers and new 
gene therapy strategies for treating RA.
8. miRNA polymorphisms
As mentioned, RA is a common, but heterogeneous, disease with the heritability about 60 
% [73]. As genetic variants are present at birth, genetic studies can help us identify the key 
genes and pathways that contribute to both occurrence and severity of disease [74]. The last 
60 years provided evidence for the genetic basis of rheumatoid arthritis by identifying genetic 
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susceptibility variants. Three basic approaches were applied to recognize these susceptibility 
loci: candidate single nucleotide polymorphisms (SNPs), linkage, and genome-wide associa-
tion studies (GWAS), which genotype thousands to millions of SNPs in large human samples. 
However, more than 10 years after the completion of the human genome sequencing project 
and numerous GWA studies, we still do not fully understand the genetic basis of RA [74, 75].
Since miRNAs are an important class of regulators of gene expression, genetic polymorphisms 
located in miRNA genes (miR-SNPs) and/or in miRNA binding sites of target genes (miR-TS-
SNPs) can act as regulatory SNPs through modifying the activity of miRNAs to affect the sus-
ceptibility to and/or severity of disease (Figure 2) [76, 77]. The miR-SNPs are thought to affect 
function in one of three ways. First, genetic alternation in miRNA genes affects its expres-
sion through the transcription of the primary transcript; second, via altering pri-miRNA and 
pre-miRNA processing; and third, by affecting the miRNA-mRNA interactions [77–79]. In 
contrast to SNPs in miRNA genes, the miR-TS-SNPs, which are present at or near a miRNA 
binding site in 3ʹ-untranslated region (UTR) of the target gene, are abundant in the human 
genome [80]. These SNPs can potentially alter miRNA function by creating as well as destroy-
ing a miRNA binding site [78]. Moreover, the functional impact of miR-TS-SNPs on disease 
phenotype largely depends on whether the corresponding miRNA is expressed in a particular 
tissue and the expression of other possibly compensatory miRNAs [77]. Prediction of SNPs 
that could alter the expression of a miRNA or its complementarily with the target genes, 
and as a result the normal function of the involved molecular pathway, seems to be of great 
importance [79]. Moreover, the polymorphisms associated with miRNAs may have a more 
important role in RA disease onset and progression than originally suspected. However, to 
date only a limited number of studies have identified miR-SNPs and/or miR-TS-SNPs rel-
evant to RA (Table 1) [81, 82]. In a genome-wide interaction analysis, miR-146a and miR-499 
have received much attention in this field. Up today, miR-146a, the most studied miRNAs in 
patients with RA, is encoded by chromosome 5q33 and can bind to the 3ʹ-UTR of many target 
mRNAs, including interleukin-1 receptor-associated kinase 1 (IRAK-1), tumor necrosis factor 
receptor-associated factor 6 (TRAF-6), and other transcripts associated with inflammatory sig-
naling [83, 84]. The common miR-146a polymorphism [85, 85], which may affect the stability 
of the miRNA, thereby influencing its expression level [82, 86], is not associated with suscep-
tibility to RA [81, 85, 87], but the miRNA-146a rs2910164 variant might increase the risk of RA 
in the female population and may influence disease activity [84]. Moreover, it remains unclear 
which allele is associated with a significantly higher level of mature miR-146a. On the other 
hand, miR-499, the gene of which is located on 20q11.22 chromosome, targets IL-17 receptor 
B (IL-17RB), IL-23a, IL-2 receptor B (IL-2Rβ), IL-6, IL-2, B- and T-lymphocyte attenuator, IL-18 
receptor (IL-18R), IL-21, peptidyl arginine deiminase type 4 (PADI4), and regulatory factor X 4 
(influences human leukocyte antigen class II expression) [83, 84]. The miR-499 polymorphism 
at position rs3746444T > C, located within the stem region of the miR-499 gene is closely asso-
ciated with the inflammation of RA and can serve a potential diagnostic biomarker for RA [81, 
84]. To date, very little is known about the role of miRNA SNPs in the pathogenesis of RA, and 
even less is known about whether it could affect miRNA-mRNA interactions. That way, the 
mechanism by which sequence variations—due to genetic or posttranscriptional changes—in 
miRNAs and/or in their target genes that modulate miRNA binding characteristics or miRNA 
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expression can affects the inflammatory processes requires further functional studies. With 
the development of large-scale RNA-sequencing methods, a new light could be shed on these 
mechanisms [80].
9. Conclusion
RA is a syndrome in which many different elements of the immune system become activated. 
A growing number of GWAS demonstrated that genetic polymorphisms, the standard genetic 
marker to identify associated alleles, make a substantial but incomplete contribution to the 
risk of RA developing. Now it is widely accepted that epigenetic mechanisms such as miR-
NAs, a class of powerful and major gene regulators, are also involved in the coordination of 
the immune processes in the rheumatoid arthritis. Both tissue and extracellular miRNAs are 
not only key molecules in the molecular mechanisms of the disease but also are very impor-
tant biomarkers for several pathological conditions and represent a promising therapeutic 
approach in future. Circulating miRNAs may be suitable for clinical use as they are stable 
present in body fluids such as plasma or serum. Recent evidence has suggested that miRNA 
levels in serum or plasma are often higher than in the synovial fluid. In addition, miRNA 
expression profiles in synovial fluids were similar to those in synovial tissues. These findings 
 Figure 2. Single nucleotide polymorphisms located in miRNAs.
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demonstrated that synovial tissues and infiltrating cells are the primary source of synovial 
fluid miRNAs. In contrast, miRNAs that are presented in the serum or plasma are released by 
several tissues and cells different from those in synovium [32]. Because rheumatoid arthritis is 
a systemic disease which can have not only a joint involvement but also other organs may be 
affected, cell-free circulating miRNA signature in serum or plasma is of great interest.
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